The authors suggest modifications to recently proposed guidelines for the management of TM.Ĭopyright © 2010 American Cancer Society. In the presence of risk factors, TM was associated with a substantially elevated risk of a concurrent diagnosis of TGCT and ITGCNU. Seventeen observational studies were identified in which the interval development of TGCT in patients with TM was reported however, the majority of those studies did not report the follow-up of a control arm and could not be summarized. Results: In final, 21 articles (including 916 children) were eligible for the final analysis that all yielded good quality and none of the citation was determined to have high risk of bias. However, in referral populations, TM was associated overall with a risk ratio of 8.5 (95% confidence interval, 4.5-16.1 P<.001) for a concurrent diagnosis of TGCT and 10.5 (95% CI, 5.3-20.8 P<.0001) for ITGCNU. Statistical analysis was performed using the Comprehensive Meta Analysis (CMA) software. The program combines ease of use with a wide array of computational options and sophisticated graphics. TM was not associated with an increased risk of TGCT in asymptomatic men. Comprehensive Meta-Analysis is a powerful computer program for meta-analysis. Thirty-three studies met inclusion criteria. In addition, studies with prospective follow-up of patients with TM were reviewed. The primary study outcomes were concurrent diagnoses of TGCT or ITGCNU, with TM. Studies were categorized according to the clinical context in which sonography was performed. Two reviewers extracted data independently. To the authors' knowledge, no previous systematic review or meta-analysis has been performed.Ī comprehensive systematic literature review was performed without language restrictions through July 2009 and included an exhaustive search of electronic databases and article references. Determining these associations is pertinent both clinically and biologically. Conversely, treatment with rosiglitazone is associated with a relevant increase in the risk of heart failure, particularly in insulin-treated patients.There is an increasing body of literature associating testicular microlithiasis (TM), a common finding on testicular ultrasound, with testicular germ cell tumor (TGCT) and intratubular germ cell neoplasia of unclassified type (ITGCNU). No increase of all-cause or cardiovascular mortality were observed with rosiglitazone.
#Comprehensive meta analysis software citation software
CONCLUSIONS: Figures for rosiglitazone-associated risk for myocardial infarction could be lower than those previously reported on the basis of a smaller number of clinical trials. FAQs about the software license, unlock codes, data entry, and citing Comprehensive Meta-Analysis. The risk of heart failure was higher (2.20) when rosiglitazone was administered as add-on therapy to insulin. (For Google Chrome use the right mouse button to save the zip-file.) In version 1. RESULTS: The OR for all-cause and cardiovascular mortality with rosiglitazone was 0.93 and 0.94, respectively rosiglitazone-associated risk for nonfatal MI and heart failure was 1.14 and 1.69, respectively. Meta-Essentials: Workbooks for meta-analysis (Version 1.5).This downloads a zip-file containing the workbooks, designed for Microsoft Excel.
METHODS: Results of 164 trials with duration >4 weeks were retrieved from and from Medline, while unpublished studies were identified from A total of 164 trials (42,922 and 45,483 patient years for rosiglitazone and comparators, respectively) were included in the analysis. Aim of this analysis is the assessment of the cardiovascular risk with rosiglitazone, using a comprehensive data set. Available meta-analyses, based on studies sponsored by GlaxoSmithKline (GSK), failed to include all trials performed with rosiglitazone. N2 - BACKGROUND: Some meta-analyses of randomized clinical trials suggested that rosiglitazone could be associated with increased risk for myocardial infarction (MI). T1 - Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
0 kommentar(er)
